# Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT00617773** · PHASE2 · COMPLETED · sponsor: **Recepta Biopharma** · enrollment: 31 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** hu3S193

## Key facts

- **NCT ID:** NCT00617773
- **Lead sponsor:** Recepta Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617773, "Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00617773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*